Disseminated Geosmithia argillacea Infection in a Patient with Ph-Positive Acute Lymphoblastic Leukemia. Case Report and Literature Review

Invasive fungal infection (IFI) remains the major complication in patients with either acute leukemia, allogeneic stem cell transplantation setting, or both, especially regarding pulmonary localization. We report an experience of a 74-year-old Caucasian male with a Philadelphia-positive (BCR-ABL p190) Common B-acute lymphoblastic leukemia (ALL) who developed a pulmonary infection due to Geosmithia argillacea. Furthermore, we describe the management of this complication and the results of microbiological tests useful to guide the treatment. All cases reported show failure of voriconazole treatment. In the majority of cases a good susceptibility to posaconazole has been reported, which seems to have a good clinical impact; however, only L-AmB shows a clinical effect to produce quick clinical improvement and so it should be a drug of choice. A literature revision shows that only a few papers have thus far described this infection, at present only one case was reported in a hematological setting like a gastrointestinal graft versus host disease in an allogeneic HSCT recipient. The severity of clinical conditions in hematological malignancy settings requires improving the management of this emerging invasive fungal infection. Indeed, a molecular diagnostic approach with a tight laboratory collaboration and targeted therapy should become the gold standard.

[1]  L. Pagano,et al.  Prophylaxis for aspergillosis in patients with haematological malignancies: pros and cons , 2018, Expert review of anti-infective therapy.

[2]  Sudhir Kumar,et al.  MEGA7: Molecular Evolutionary Genetics Analysis Version 7.0 for Bigger Datasets. , 2016, Molecular biology and evolution.

[3]  V. Pavone,et al.  Pre-chemotherapy risk factors for invasive fungal diseases: prospective analysis of 1,192 patients with newly diagnosed acute myeloid leukemia (SEIFEM 2010-a multicenter study) , 2015, Haematologica.

[4]  Kyung Sun Park,et al.  Isolation and Identification of Geosmithia argillacea from a Fungal Ball in the Lung of a Tuberculosis Patient , 2013, Annals of laboratory medicine.

[5]  M. Asslaber,et al.  Disseminated Geosmithia argillacea infection in a patient with gastrointestinal GvHD , 2012, Bone Marrow Transplantation.

[6]  S. Holland,et al.  Geosmithia argillacea: an emerging cause of invasive mycosis in human chronic granulomatous disease. , 2011, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[7]  O. Lortholary,et al.  Emergence of Disseminated Infections Due to Geosmithia argillacea in Patients with Chronic Granulomatous Disease Receiving Long-Term Azole Antifungal Prophylaxis , 2011, Journal of Clinical Microbiology.

[8]  L. Mély,et al.  Geosmithia argillacea: an Emerging Pathogen in Patients with Cystic Fibrosis , 2010, Journal of Clinical Microbiology.

[9]  J. Houbraken,et al.  Isolation of the Fungus Geosmithia argillacea in Sputum of People with Cystic Fibrosis , 2010, Journal of Clinical Microbiology.

[10]  B. Wickes,et al.  Disseminated Geosmithia argillacea infection in a German shepherd dog. , 2009, Medical mycology.

[11]  J. Perfect,et al.  Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia. , 2007, The New England journal of medicine.

[12]  M. Falagas,et al.  Fluconazole versus itraconazole for antifungal prophylaxis in neutropenic patients with haematological malignancies: a meta‐analysis of randomised‐controlled trials , 2005, British journal of haematology.

[13]  D. Kontoyiannis,et al.  Epidemiology and outcome of zygomycosis: a review of 929 reported cases. , 2005, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[14]  O. Cornely,et al.  Evidence-based assessment of primary antifungal prophylaxis in patients with hematologic malignancies. , 2003, Blood.

[15]  S J Lin,et al.  Aspergillosis case-fatality rate: systematic review of the literature. , 2001, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[16]  B. Lebeau,et al.  Candidemia in cancer patients: a prospective, multicenter surveillance study by the Invasive Fungal Infection Group (IFIG) of the European Organization for Research and Treatment of Cancer (EORTC). , 1999, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[17]  E. Anaissie,et al.  Fusarium, a significant emerging pathogen in patients with hematologic malignancy: ten years' experience at a cancer center and implications for management. , 1997, Blood.

[18]  N. L. Glass,et al.  Development of primer sets designed for use with the PCR to amplify conserved genes from filamentous ascomycetes , 1995, Applied and environmental microbiology.

[19]  L. Pagano,et al.  Design and Methods , 2022 .